In this interview, Sarah Griffin from Informa Markets provides a review of CPHI Americas 2025 and teases some potential exciting innovations being planned for the 2026 edition of the conference.

Epigenetic modulation has been important in the development of oncology therapies, but its use in cardiovascular diseases is just beginning. In this pre-BIO interview, Sten Sörensen from Cereno Scientific provides some insights into developments in this field.

Prior to BIO 2025, Russell Miller from Enzene Biosciences highlights how a fully connected continuous manufacturing platform is enhancing biologics production and, hence, improving patient access.

Solid tumors are difficult to treat as a result of numerous factors, in this interview, Oury Chetboun from Seekyo Therapeutics, details how targeting functional proteins in the tumor microenvironment can help.

Treating metastases with an external laser beam can prove challenging; however, radiotherapeutics are providing more targeted treatment options, radiating the tumor cells from within, specifies David Bejker from Affibody.

Elin Trampe from Dicot Pharma emphasizes the need for innovation in the field of potency drugs, which has been dominated by PDE5 inhibitors, and provides details of an approach that is offering new potential.

The development and manufacture of personalized therapies are challenging for a variety of reasons; however, novel tools that are fit-for-purpose are becoming available, notes Luc Henry from Limula.

For David Westberg from Nanexa, long-acting injectables will continue to see growth in the field of mental health conditions and will also experience dramatic growth in other indication areas, such as Type 2 diabetes and obesity.

Multi-omics is allowing oversight into the relationships between the different layers of cells, allowing for the creation of new types of drugs and treatment strategies, explains Juozas Gordevičius from VUGENE.

Ahead of BIO 2025, Monika Paulė from Caszyme reveals details about a new CRISPR family, Cas12l, which is smaller than Cas9, meaning it could be a good alternative option for companies with certain limitations.

As a result of the capability to be used across multiple therapeutic programs, the U.S. regulatory body has granted Sarepta’s AAVrh74 platform with platform technology designation.

This approval, which was based on the results of a Phase III trial demonstrating a higher relative efficiency of the new vaccine compared with the old version, marks the third for the company from the FDA.

The complexities of next-generation therapies are pushing the boundaries of development and manufacture, leading to an increased need for advanced technologies and novel approaches to processes.

While the spread of misinformation about vaccines is contributing to greater vaccine hesitancy, global rates of measles outbreaks are rising at alarming rates, leading to warnings being issued to international travelers.

The proposed acquisition will expand Sanofi’s immunological portfolio with a precision medicine already approved for the treatment of ASM and ISM, a next-gen highly selective kinase inhibitor, and an investigational oral drug.

The latest studies on the mechanism of action for LIB-01 have demonstrated that the drug targets the underlying nerves and vascular structures that are involved in penile erections.

The company has added the further sterile fill/finish capacity to the site in response to continued growth in demand for its drug product services.

During Pharmatag 2025, Syntegon presented its new SynTiso aseptic filling line at Pharmatag 2025, which has been developed in collaboration with partners from the pharmaceutical industry to meet the increasing need for flexibility, contamination control, and Annex 1 compliance.

As CPHI Americas wraps up for another year, we look back at some of the highlights from the conference and exhibition hall, and provide a sneak peek of a great opportunity at CPHI Frankfurt.

Porton Advanced has announced separate partnerships with TongEYE and Hualong Biological, as it moves into regenerative therapies for vision loss and innovative immunotherapies for solid tumors.